Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial.
Saved in:
| Title: | Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial. |
|---|---|
| Authors: | Natali A; Department of Clinical and Experimental Medicine, Pisa University, Via Savi 27, 56100, Pisa, Italy., Nesti L; Department of Clinical and Experimental Medicine, Pisa University, Via Savi 27, 56100, Pisa, Italy. lorenzonesti90@gmail.com., Fabiani I; Department of Surgery, Medical, Molecular, and Critical Area Pathology, Pisa University, Pisa, Italy., Calogero E; Department of Surgery, Medical, Molecular, and Critical Area Pathology, Pisa University, Pisa, Italy., Di Bello V; Department of Surgery, Medical, Molecular, and Critical Area Pathology, Pisa University, Pisa, Italy. |
| Source: | Cardiovascular diabetology [Cardiovasc Diabetol] 2017 Oct 12; Vol. 16 (1), pp. 130. Date of Electronic Publication: 2017 Oct 12. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840 (Electronic) Linking ISSN: 14752840 NLM ISO Abbreviation: Cardiovasc Diabetol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 29025406 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Natali+A%22">Natali A</searchLink>; Department of Clinical and Experimental Medicine, Pisa University, Via Savi 27, 56100, Pisa, Italy.<br /><searchLink fieldCode="AU" term="%22Nesti+L%22">Nesti L</searchLink>; Department of Clinical and Experimental Medicine, Pisa University, Via Savi 27, 56100, Pisa, Italy. lorenzonesti90@gmail.com.<br /><searchLink fieldCode="AU" term="%22Fabiani+I%22">Fabiani I</searchLink>; Department of Surgery, Medical, Molecular, and Critical Area Pathology, Pisa University, Pisa, Italy.<br /><searchLink fieldCode="AU" term="%22Calogero+E%22">Calogero E</searchLink>; Department of Surgery, Medical, Molecular, and Critical Area Pathology, Pisa University, Pisa, Italy.<br /><searchLink fieldCode="AU" term="%22Di+Bello+V%22">Di Bello V</searchLink>; Department of Surgery, Medical, Molecular, and Critical Area Pathology, Pisa University, Pisa, Italy. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101147637%22">Cardiovascular diabetology</searchLink> [Cardiovasc Diabetol] 2017 Oct 12; Vol. 16 (1), pp. 130. <i>Date of Electronic Publication: </i>2017 Oct 12. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BioMed+Central%22">BioMed Central </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101147637 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1475-2840 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214752840%22">14752840 </searchLink><i>NLM ISO Abbreviation: </i>Cardiovasc Diabetol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=29025406 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1186/s12933-017-0615-6 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 130 Titles: – TitleFull: Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Natali A – PersonEntity: Name: NameFull: Nesti L – PersonEntity: Name: NameFull: Fabiani I – PersonEntity: Name: NameFull: Calogero E – PersonEntity: Name: NameFull: Di Bello V IsPartOfRelationships: – BibEntity: Dates: – D: 12 M: 10 Text: 2017 Oct 12 Type: published Y: 2017 Identifiers: – Type: issn-electronic Value: 1475-2840 Numbering: – Type: volume Value: 16 – Type: issue Value: 1 Titles: – TitleFull: Cardiovascular diabetology Type: main |
| ResultId | 1 |
